Alnylam Pharmaceuticals Inc
ALNY
View Detailed Chart
397.550USD
-15.080-3.65%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
52.39BMarket Cap
1224.25P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.65%
5 Days
-13.22%
1 Month
-11.49%
6 Months
+29.08%
Year to Date
+68.95%
1 Year
+61.97%
View Detailed Chart
TradingKey Stock Score of Alnylam Pharmaceuticals Inc
Currency: USD Updated: 2025-12-12Key Insights
Alnylam Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 28/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 486.19.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alnylam Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
31
analysts
Buy
Current Rating
486.195
Target Price
+13.06%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Alnylam Pharmaceuticals Inc Highlights
StrengthsRisks
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 116.72% year-on-year.
Overvalued
The company’s latest PE is 1224.25, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 132.38M shares, decreasing 0.01% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.39.
Alnylam Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alnylam Pharmaceuticals Inc Info
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Ticker SymbolALNY
CompanyAlnylam Pharmaceuticals Inc
CEOGreenstreet (Yvonne L)
Websitehttps://www.alnylam.com/
FAQs
What is the current price of Alnylam Pharmaceuticals Inc (ALNY)?
The current price of Alnylam Pharmaceuticals Inc (ALNY) is 397.550.
What is the symbol of Alnylam Pharmaceuticals Inc?
The ticker symbol of Alnylam Pharmaceuticals Inc is ALNY.
What is the 52-week high of Alnylam Pharmaceuticals Inc?
The 52-week high of Alnylam Pharmaceuticals Inc is 495.550.
What is the 52-week low of Alnylam Pharmaceuticals Inc?
The 52-week low of Alnylam Pharmaceuticals Inc is 205.870.
What is the market capitalization of Alnylam Pharmaceuticals Inc?
The market capitalization of Alnylam Pharmaceuticals Inc is 52.39B.
What is the net income of Alnylam Pharmaceuticals Inc?
The net income of Alnylam Pharmaceuticals Inc is -278.16M.
Is Alnylam Pharmaceuticals Inc (ALNY) currently rated as Buy, Hold, or Sell?
According to analysts, Alnylam Pharmaceuticals Inc (ALNY) has an overall rating of Buy, with a price target of 486.195.
What is the Earnings Per Share (EPS TTM) of Alnylam Pharmaceuticals Inc (ALNY)?
The Earnings Per Share (EPS TTM) of Alnylam Pharmaceuticals Inc (ALNY) is 0.325.
Related Instruments
+1.83%
+0.76%
-0.31%
-0.51%
+0.15%
+1.33%
+0.11%
-0.23%
-2.28%
+0.23%
-0.37%
+1.37%
+2.40%
-0.23%
-0.16%
-0.73%
-0.74%
0.00%
-1.30%Popular Symbols
